ALFA FinderNSE filing, NSE: TARC. Summary written from the filing by ALFA Finder's alert engine.
TARC Ltd: key numbers
- Share price
- ₹133.44
- Market cap
- ₹3,938 Cr
- Revenue (annual)
- ₹329.8 Cr
- Net profit (annual)
- ₹19.07 Cr
- P/E (TTM)
- -314.8×Sector 38.0×
- Promoter holding
- 65.12%+0.00% QoQ
- FII holding
- 1.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TARC Ltd
All →TARC Investor Presentation: Key Takeaways
Q2 FY27 consolidated total income ₹134.07 Cr (vs ₹34.10 Cr) and PAT ₹4.05 Cr. H1 pre-sales ₹955 Cr (+69% YoY), H1 EBITDA ₹44.6 Cr.
TARC Q2 FY27 Results: Turns Profitable, Net Profit ₹4.4 Cr
TARC Ltd reported revenue from operations of ₹128.8 Cr (+1766.7% YoY) and net profit of ₹4.4 Cr for Q2 FY27.
- Key figure
- Net profit ₹4.4 Cr
TARC Management Change
TARC's independent director Ambarish Chatterjee completes his second and final term on 9 November 2026. The Board also reconstituted its committees effective 10 November 2026.
TARC Board Meeting Date
TARC Ltd intimated that its Board will meet on 5 Nov 2026. The agenda includes approving unaudited H1 FY27 financial results.
TARC Other Announcement
TARC Limited has filed its quarterly shareholding pattern for the period ending September 30, 2026, as per regulatory requirements.
TARC Annual General Meeting
TARC Limited conducted its 10th Annual General Meeting on September 19, 2026. The meeting covered financial statement adoption and director appointments alongside remuneration revisions.
Other results update announcements
All →Niyogin Fintech Results Update
Niyogin Fintech's CEO letter reports Q2 FY27 net revenue of Rs 23.9 Cr and PBT ex-ESOP loss of Rs 4.4 Cr. Composite scheme awaits final NCLT approval.
Prakash Pipes Results Update
Prakash Pipes reported Q2 FY27 net sales of ₹259 crores, up 43%, with PAT rising 72% to ₹16 crores. Half-year net sales reached ₹501 crores.
Gaudium IVF And Women Health Results Update
Gaudium IVF reported Q2 FY27 revenue of ₹37.4 crore, up 17.9% YoY, with H1 revenue at ₹56.8 crore. Two new IVF hubs commenced operations during the quarter.
Systematix Corporate Services Results Update
Systematix's Q2 FY27 adjusted revenue rose 102% QoQ to ₹56.04 crore, with PAT of ₹13.13 crore. Year-on-year revenue was flat, while H1 PAT fell to ₹8.24 crore.
Balaxi Pharmaceuticals Results Update
Balaxi Pharmaceuticals issued a press release on Q2 FY27 results, with revenue up 45% and PAT up 450% year-on-year. EBITDA rose 338% to ₹512.07 lakh.
Q-Line Biotech Results Update
Q-Line Biotech's H1 FY27 revenue rose 5.83% while EBITDA grew 10.02%, but PAT fell 8.06%. The release also covers a proposed 70% stake acquisition in Heidelco.